Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/5299
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEdwards, Anna-
dc.contributor.authorBrett GM, Hughes-
dc.contributor.authorBrown, Teresa-
dc.contributor.authorJudith, Bauer-
dc.date.accessioned2023-08-03T04:49:09Z-
dc.date.available2023-08-03T04:49:09Z-
dc.date.issued2022-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/5299-
dc.description.abstractSarcopenia is a known independent prognostic factor for decreased survival in patients with head and neck cancer; yet, its importance for the growing number of younger patients diagnosed with human papillomavirus (HPV)–positive oropharyngeal carcinoma (OPC+) has not been established. This systematic literature review aimed to determine the prevalence and impact of computed tomography (CT)–defined sarcopenia on survival outcomes for adult OPC+ patients (>18 y) undergoing any treatment modality. Prospective studies were searched using PubMed, Embase, CENTRAL, CINAHL, and Web of Science up until and including February 2022. Bias was assessed using the Quality In Prognosis Studies (QUIPS) tool, and certainty of evidence using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. In total, 9 studies (total pooled OPC+ patients, n = 744) were identified and included in this review; 2 at low, 6 at moderate, and 1 at high risk of bias. All studies varied in sarcopenia assessment methods and skeletal muscle index threshold cutoff values. These studies demonstrated the cumulative prevalence of sarcopenia for OPC+ patients to be 42.9% (95% CI: 37.8%, 47.9%). While overall survival (3 studies, n = 253) and progression-free survival (1 study, n = 117) was lower in sarcopenic OPC+ patients, this was not statistically significant. GRADE certainty of evidence for impact of pretreatment sarcopenia on overall survival was low and progression-free survival was very low. Although these studies showed there to be a high prevalence of pretreatment sarcopenia in patients with OPC+, which may decrease survival, the impact on progression-free survival is very uncertain. Further, high-quality research utilizing consistent sarcopenia definitions and assessment methods that are conducted specifically in OPC+ is required to strengthen evidence certainty and determine if sarcopenia is an independent prognostic factor for this populationen_US
dc.language.isoen_USen_US
dc.subjectsarcopeniaen_US
dc.subjecthuman papillomavirusen_US
dc.subjecthead and neck canceren_US
dc.subjectnutritionen_US
dc.subjectsurvivaen_US
dc.titlePrevalence and Impact of Computed Tomography–Defined Sarcopenia on Survival in Patients with Human Papillomavirus–Positive Oropharyngeal Cancer: A Systematic Reviewen_US
dc.typeArticleen_US
Appears in Collections:VOL 13 NO 6 2022

Files in This Item:
File Description SizeFormat 
2433-2444.pdf3.09 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.